Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 versus tacrolimus-based immunosuppression in de novo and maintenance kidney transplant recipients
NL-OMON55663Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of iscalimab in kidney transplant (5 cohorts), sponsored by Novartis. Primary endpoint: Composite efficacy failure over 12 months post-transplantation or post-conversion. Started Jan 2019; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON55663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55663.